Fortress Biotech (FBIO) vs Gain Therapeutics (GANX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Gain Therapeutics (GANX) has outperformed Fortress Biotech (FBIO) over the past year, losing 22.0% versus a loss of 28.2%. Over five years, GANX leads with a -76.7% price change compared with -95.6% for FBIO. Gain Therapeutics is the larger company by market cap ($70.5 million vs $69.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FBIO | GANX |
|---|---|---|
| Share price | $2.09 | $1.62 |
| Market cap | $69.70M | $70.48M |
| 1-day change | +2.45% | -3.29% |
| YTD return | -42.90% | -49.84% |
| 1-year return | -28.18% | -21.98% |
| 5-year return | -95.58% | -76.73% |
| P/E ratio (TTM) | 0.76 | — |
| EPS (TTM) | $2.76 | $-0.50 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.53 | $4.34 |
| 52-week low | $2.00 | $1.53 |
| Distance from 52-week high | -53.86% | -62.79% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +139.23% | +345.82% |
| Average volume | 507.86K | 493.98K |
| Shares outstanding | 33.35M | 43.64M |
| Employees | 78 | 20 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Fortress Biotech
FBIO stock →Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for the treatment of axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne; Amzeeq, a minocycline topical foam for the treatment of lesions of non-nodular moderate to severe acne vulgaris; Zilxi, a minocycline topical foam for the treatment of lesions of rosacea; Exelderm, an antifungal cream for topical use; Targadox, an oral doxycycline drug for the therapy of severe acne; Luxamend, a water-based emulsion for the treatment of superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, first and second-degree burns, and radiation dermatitis; and UNLOXCYT, a death-ligand 1 blocking antibody for the treatment of metastatic cutaneous squamous cell carcinoma.
Healthcare · Biotechnology · 78 employees
About Gain Therapeutics
GANX stock →Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. The company's drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.
Healthcare · Biotechnology · 20 employees
FBIO vs GANX FAQ
Which is bigger, Fortress Biotech or Gain Therapeutics?
Gain Therapeutics (GANX) is larger, with a market capitalization of $70.48M compared with $69.70M for Fortress Biotech (FBIO).
Which stock has performed better over the past year, FBIO or GANX?
GANX returned -21.98% over the past 12 months, compared with -28.18% for FBIO (price return, excluding dividends). Past performance does not predict future results.
Are Fortress Biotech and Gain Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.